NASDAQ:CTSO Cytosorbents Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cytosorbents Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.82 -0.37 (-4.52 %) (As of 09/23/2020 03:51 PM ET) Add Compare Share Today's Range$7.79Now: $7.82▼$8.2450-Day Range$7.37MA: $8.50▼$9.6652-Week Range$3.49Now: $7.82▼$11.74Volume4,864 shsAverage Volume659,615 shsMarket Capitalization$337.50 millionP/E RatioN/ADividend YieldN/ABeta0.48 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol, a development stage blood purification technology; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCytosorbents has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.17, Cytosorbents has a forecasted upside of 93.9% from its current price of $7.82.Amount of Analyst CoverageCytosorbents has only been the subject of 3 research reports in the past 90 days. Previous Next 3.5 Community Rank Outperform VotesCytosorbents has received 426 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCytosorbents has received 182 “underperform” votes. (Add your “underperform” vote.)Community SentimentCytosorbents has received 70.07% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote “Outperform” if you believe CTSO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 26.11% of the stock of Cytosorbents is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.34) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -15.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -15.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 71.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTSO Previous Symbol CUSIPN/A CIK1175151 Webwww.cytosorbents.com Phone732-329-8885Debt Debt-to-Equity Ratio0.35 Current Ratio2.68 Quick Ratio2.55Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$24.95 million Price / Sales13.53 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book71.09Profitability EPS (Most Recent Fiscal Year)($0.60) Net Income$-19,270,000.00 Net Margins-53.56% Return on Equity-122.99% Return on Assets-45.88%Miscellaneous Employees125 Outstanding Shares43,158,000Market Cap$337.50 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $7.82 -0.37 (-4.52 %) (As of 09/23/2020 03:51 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CTSO News and Ratings via Email Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter. Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions How has Cytosorbents' stock price been impacted by COVID-19 (Coronavirus)? Cytosorbents' stock was trading at $4.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CTSO shares have increased by 64.6% and is now trading at $7.85. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cytosorbents? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytosorbents. When is Cytosorbents' next earnings date? Cytosorbents is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Cytosorbents. How were Cytosorbents' earnings last quarter? Cytosorbents Corp (NASDAQ:CTSO) posted its earnings results on Tuesday, August, 4th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). The medical research company had revenue of $9.80 million for the quarter, compared to the consensus estimate of $9.79 million. Cytosorbents had a negative return on equity of 122.99% and a negative net margin of 53.56%. View Cytosorbents' earnings history. What guidance has Cytosorbents issued on next quarter's earnings? Cytosorbents updated its second quarter 2020 After-Hours earnings guidance on Monday, July, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.8-9.8 million, compared to the consensus revenue estimate of $9.25 million. What price target have analysts set for CTSO? 6 Wall Street analysts have issued 12-month target prices for Cytosorbents' stock. Their forecasts range from $14.00 to $17.00. On average, they anticipate Cytosorbents' share price to reach $15.17 in the next twelve months. This suggests a possible upside of 93.2% from the stock's current price. View analysts' price targets for Cytosorbents. Who are some of Cytosorbents' key competitors? Some companies that are related to Cytosorbents include Cardiovascular Systems (CSII), Atrion (ATRI), Luminex (LMNX), Cerus (CERS), GenMark Diagnostics (GNMK), OraSure Technologies (OSUR), Orthopediatrics (KIDS), Acutus Medical (AFIB), MiMedx Group (MDXG), Cryolife (CRY), Vapotherm (VAPO), SI-Bone (SIBN), LeMaitre Vascular (LMAT), Tactile Systems Technology (TCMD) and Invo Bioscience (IVOB). View all competitors. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Pfizer (PFE), AbbVie (ABBV) and Opko Health (OPK). Who are Cytosorbents' key executives? Cytosorbents' management team includes the following people: Dr. Phillip P. Chan, CEO, Pres & Director (Age 49)Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 64)Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 61)Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 80) What is Cytosorbents' stock symbol? Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO." Who are Cytosorbents' major shareholders? Cytosorbents' stock is owned by many different retail and institutional investors. Top institutional investors include Skylands Capital LLC (3.29%), Sargent Investment Group LLC (1.62%), Goldman Sachs Group Inc. (0.43%), EAM Investors LLC (0.38%), Bank of New York Mellon Corp (0.36%) and Nuveen Asset Management LLC (0.33%). Company insiders that own Cytosorbents stock include Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View institutional ownership trends for Cytosorbents. Which major investors are selling Cytosorbents stock? CTSO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Advisor Group Holdings Inc., and Bank of New York Mellon Corp. View insider buying and selling activity for Cytosorbents. Which major investors are buying Cytosorbents stock? CTSO stock was bought by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, Goldman Sachs Group Inc., Engineers Gate Manager LP, Skylands Capital LLC, Cubist Systematic Strategies LLC, California Public Employees Retirement System, Trexquant Investment LP, and EAM Investors LLC. Company insiders that have bought Cytosorbents stock in the last two years include Kathleen P Bloch, and Phillip P Chan. View insider buying and selling activity for Cytosorbents. How do I buy shares of Cytosorbents? Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cytosorbents' stock price today? One share of CTSO stock can currently be purchased for approximately $7.85. How big of a company is Cytosorbents? Cytosorbents has a market capitalization of $338.79 million and generates $24.95 million in revenue each year. The medical research company earns $-19,270,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. Cytosorbents employs 125 workers across the globe. What is Cytosorbents' official website? The official website for Cytosorbents is www.cytosorbents.com. How can I contact Cytosorbents? Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
